While future toxicological studies are needed to thoroughly assess the tolerability of chronic PDDC prior to clinical trials, based on the current data, PDDC represents a promising new therapeutic with the potential to slow the progression of AD by reducing the spread of hyperphosphorylated tau species. The gene discussed is MAPT; the disease is Alzheimer disease.